Switch theme
Sign up to access all valuation multiples
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
2012
14
LTM Revenue $9.6M
LTM EBITDA -$19.1M
$161M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hyloris Pharmaceuticals has a last 12-month revenue (LTM) of $9.6M and a last 12-month EBITDA of -$19.1M.
In the most recent fiscal year, Hyloris Pharmaceuticals achieved revenue of $9.5M and an EBITDA of -$6.3M.
Hyloris Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hyloris Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.6M | XXX | $9.5M | XXX | XXX | XXX |
| Gross Profit | $9.6M | XXX | $9.2M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$19.1M | XXX | -$6.3M | XXX | XXX | XXX |
| EBITDA Margin | -200% | XXX | -66% | XXX | XXX | XXX |
| EBIT | -$18.5M | XXX | -$7.2M | XXX | XXX | XXX |
| EBIT Margin | -193% | XXX | -75% | XXX | XXX | XXX |
| Net Profit | -$19.6M | XXX | -$7.1M | XXX | XXX | XXX |
| Net Margin | -205% | XXX | -75% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hyloris Pharmaceuticals's stock price is EUR 6 (or $7).
Hyloris Pharmaceuticals has current market cap of EUR 165M (or $186M), and EV of EUR 143M (or $161M).
See Hyloris Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $161M | $186M | XXX | XXX | XXX | XXX | $-0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hyloris Pharmaceuticals has market cap of $186M and EV of $161M.
Hyloris Pharmaceuticals's trades at 17.0x EV/Revenue multiple, and -25.5x EV/EBITDA.
Equity research analysts estimate Hyloris Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hyloris Pharmaceuticals has a P/E ratio of -9.5x.
See valuation multiples for Hyloris Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $186M | XXX | $186M | XXX | XXX | XXX |
| EV (current) | $161M | XXX | $161M | XXX | XXX | XXX |
| EV/Revenue | 16.8x | XXX | 17.0x | XXX | XXX | XXX |
| EV/EBITDA | -8.4x | XXX | -25.5x | XXX | XXX | XXX |
| EV/EBIT | -8.7x | XXX | -22.5x | XXX | XXX | XXX |
| EV/Gross Profit | 16.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.5x | XXX | -26.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -19.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHyloris Pharmaceuticals's last 12 month revenue growth is 135%
Hyloris Pharmaceuticals's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.2M for the same period.
Hyloris Pharmaceuticals's rule of 40 is -583% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hyloris Pharmaceuticals's rule of X is 137% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hyloris Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 135% | XXX | 98% | XXX | XXX | XXX |
| EBITDA Margin | -200% | XXX | -66% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -583% | XXX | 68% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 137% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 121% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 173% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hyloris Pharmaceuticals acquired XXX companies to date.
Last acquisition by Hyloris Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Hyloris Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hyloris Pharmaceuticals founded? | Hyloris Pharmaceuticals was founded in 2012. |
| Where is Hyloris Pharmaceuticals headquartered? | Hyloris Pharmaceuticals is headquartered in Belgium. |
| How many employees does Hyloris Pharmaceuticals have? | As of today, Hyloris Pharmaceuticals has 14 employees. |
| Is Hyloris Pharmaceuticals publicy listed? | Yes, Hyloris Pharmaceuticals is a public company listed on BRU. |
| What is the stock symbol of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals trades under HYL ticker. |
| When did Hyloris Pharmaceuticals go public? | Hyloris Pharmaceuticals went public in 2020. |
| Who are competitors of Hyloris Pharmaceuticals? | Similar companies to Hyloris Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals's current market cap is $186M |
| What is the current revenue of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals's last 12 months revenue is $9.6M. |
| What is the current revenue growth of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals revenue growth (NTM/LTM) is 135%. |
| What is the current EV/Revenue multiple of Hyloris Pharmaceuticals? | Current revenue multiple of Hyloris Pharmaceuticals is 16.8x. |
| Is Hyloris Pharmaceuticals profitable? | Yes, Hyloris Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals's last 12 months EBITDA is -$19.1M. |
| What is Hyloris Pharmaceuticals's EBITDA margin? | Hyloris Pharmaceuticals's last 12 months EBITDA margin is -200%. |
| What is the current EV/EBITDA multiple of Hyloris Pharmaceuticals? | Current EBITDA multiple of Hyloris Pharmaceuticals is -8.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
